Wall Street is positive on ACADIA Pharmaceuticals Inc. (ACAD). On average, analysts give ACADIA Pharmaceuticals Inc. a Buy rating. The average price target is $25.8, which means analysts expect the stock to rise by 62.26% over the next twelve months. That average ranking earns ACADIA Pharmaceuticals Inc. an Analyst Rating of 19, which is better than 19% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ACAD a Buy today. Find out what this means to you and get the rest of the rankings on ACAD!